We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00896740
First Posted: May 12, 2009
Last Update Posted: December 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Grover Bagby, OHSU Knight Cancer Institute
May 9, 2009
May 12, 2009
December 4, 2017
March 2002
September 2007   (Final data collection date for primary outcome measure)
  • Comparison of Fanconi anemia (FA) hematopoietic cells vs normal hematopoietic cells
  • Comparison of FA hematopoietic cells from children with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) vs children (siblings) with FA but without MDS/AML
  • Comparison of FA cells from different complementation groups
Same as current
Complete list of historical versions of study NCT00896740 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants
Analysis of Fanconi Anemia Gene Function by Microarray Analysis of Bone Marrow Cells

RATIONALE: Studying samples of bone marrow from patients with Fanconi anemia and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to Fanconi anemia.

PURPOSE: This laboratory study is evaluating gene function in bone marrow cells from patients with Fanconi anemia and from healthy participants.

OBJECTIVES:

  • Describe the complete hematopoietic transcriptomes of Fanconi cells of every common complementation group (e.g., A, C, G, and F) as well as transcriptomes of neoplastic cells derived from bone marrow of patients with Fanconi anemia.
  • Define large-scale dynamic gene expression data in these patients.

OUTLINE: This is a multicenter study.

Patients and healthy volunteers undergo bone marrow aspiration or biopsy for biological studies. Samples are analyzed for gene expression profiles using microarray assays.

PROJECTED ACCRUAL: A total of 80 patients and 10 healthy volunteers will be accrued for this study.

Observational
Observational Model: Case-Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
FA Patients are recruited from OHSU Clinics. Healthy Normal donors are recruited with an IRB approved advertisement which runs in the Outlook and is posted on bulletin boards around campus
Fanconi Anemia
  • Genetic: microarray analysis
  • Procedure: biopsy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
90
September 2007
September 2007   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Meets 1 of the following criteria:

    • Diagnosis of Fanconi anemia

      • Requires bone marrow aspiration or biopsy for clinical purposes
    • Healthy volunteer

      • Over 18 years of age
      • No known blood abnormality

PATIENT CHARACTERISTICS:

  • Platelet count > 150,000/mm^3
  • White Blood Cell(WBC) > 4,000/mm^3
  • Hemoglobin > 13 g/dL
  • No clinical signs or symptoms of acute or subacute infection (e.g., viral, bacterial, or fungal)
  • No allergies to lidocaine or xylocaine

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: All
1 Year to 55 Years   (Child, Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00896740
IRB00000713
OHSU-HEM-01079-L
CDR0000445212 ( Other Identifier: NCI PDQ )
Yes
Not Provided
Not Provided
Grover Bagby, OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Grover C. Bagby, MD OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
November 2017